These findings point to a switch from ERα-dependent to HER2-dependent/ERα-independent expression of FOXM1 when patients progress under endocrine treatment, even in ER+ breast cancer without HER2 amplification or without activating HER2 mutations (Figure 7). This evidence concerns the gene ERBB2 and breast carcinoma.